Novo Nordisk

Signal: Wegovy cuts cardiovascular risk by 20% for heart disease patients

Novo Nordisk’s blockbuster weight-loss drug Wegovy may reduce the risk of heart attack before the weight loss effects take place,…

Novo Nordisk to close kidney outcomes trial for Ozempic

Novo Nordisk has announced that it will stop the kidney outcomes trial for the company’s blockbuster drug, Ozempic, even after…

Signal: Novo Nordisk market cap higher than Danish GDP due to obesity drugs

Novo Nordisk, manufacturer of GLP-1 antagonist drugs Wegovy and Ozempic, now has a higher market capitalisation than the yearly GDP…

Novo Nordisk acquires Ziylo in a deal valued up to $800m

Novo Nordisk has acquired 100% of shares in UK-based biotechnology firm Ziylo under a potential deal worth more than $800m.…